Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.

Troya, Jesús; Ryan, Pablo; Ribera, Esteban; Podzamczer, Daniel; Hontañón, Victor; Terrón, Jose Alberto; Boix, Vicente; Moreno, Santiago et al. · PLoS One · 2017

retrospective_cohort · Level III

Where this comes from

Record sourced from PubMed, PMID 28182783.
Also identified by DOI 10.1371/journal.pone.0172184 and PMC identifier 5300180.
No licence information is recorded for this record.
Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0164455.].

Read the full text

View on PubMed · Publisher (DOI)